Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
With
Otsuka Pharmaceutical Co., Ltd.
This extension safety study was terminated early because one of the lead-in studies (14571A) in elderly was terminated and because the Sponsor considered that sufficient long-term safety data has already been collected in the development programme in the population aged 18-65 yrs.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient is judged to benefit from adjunctive treatment with brexpiprazole according to the clinical opinion of the investigator.
The patient had MDD at entry in lead-in brexpiprazole studies, NCT01838681 / 14570A or NCT01837797 / 14571A, diagnosed according to DSM-IV-TR™.
The patient agrees to protocol-defined use of effective contraception.
You may not be if
The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
The patient has been diagnosed with a psychiatric disorder other than MDD during the lead-in studies NCT01838681 / 14570A or NCT01837797 / 14571A.
The patient, in the opinion of the investigator or according to C-SSRS, is at significant risk of suicide.
The patient has any relevant medical history or current presence of systemic disease.
The patient has, at the Baseline Visit an abnormal ECG that is, in the investigator's opinion, clinically significant.
The patient has a moderate or severe ongoing adverse event related to study medication from the lead-in studies considered of potential safety risk by the investigator.
The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.